Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antifungal drug
Biotech
Pulmocide pulls ph. 3 antifungal trial over mortality rate
The British biotech is now performing a thorough review of the trial data to determine the future of its opelconazole program.
Darren Incorvaia
Jan 7, 2026 10:57am
Newfound compound kills multi-drug-resistant fungi
Mar 19, 2025 12:00pm
F2G raises $100M for 2nd attempt to get new antifungal to market
Sep 12, 2024 8:58am
Pulmocide exits OPERA with evidence of antifungal efficacy
Apr 15, 2024 9:41am
Drug has power of nature's strongest antibiotic, but less toxic
Nov 9, 2023 10:30am
Cidara wins near-unanimous AdComm support despite data doubts
Jan 25, 2023 10:17am